Commitments for the acquisition of intangible assets 37. relateD party transactions (1) Major companies the Group controls 38. contingent liaBilities Legal Proceedings Astellas Pharma Inc.  _ Annual Report 2014 148 The Group has entered into research and development col- laborations and in-license agreements of products and tech- nologies with a number of third parties. These agreements  may require the Group to make milestone payments upon the  achievement of agreed objectives or when certain conditions  are met as defined in the agreements. “Sales milestone payments” represent obligations to pay the  amount set out in an individual contract agreement upon  achievement of a milestone determined according to the target  of sales. The amounts shown in the table above represent the maxi- mum payments to be made when all milestones are achieved,  and they are undiscounted and not risk adjusted. Since the  achievement of the conditions for payment is highly uncertain,  it is unlikely that they will all fall due and the amounts of the  actual payments may vary considerably from those stated in  the table. “Research and development milestone payments” represent  obligations to pay the amount set out in an individual contract  agreement upon achievement of a milestone determined  according to the stage of research and development. A list of major companies the Group controls is presented in “Principal Subsidiaries and Affiliates”. The table below shows, by the type, the compensation of key management personnel: Key management personnel consist of 21 people (22 during 2013) including directors, corporate auditors and members of the  global management committee. The Group is involved in various claims and legal proceedings  of a nature considered common to the pharmaceutical indus- try. These proceedings are generally related to product liability  claims, competition and antitrust law, intellectual property  matters, employment claims, and government investigations.  In general, since litigation and other legal proceedings contain  many uncertainties and complex factors, it is often not pos- sible to make reliable judgment regarding the possibility of  losses nor to estimate expected financial effect if these matters  are decided in a manner that is adverse to the Group. In these  cases, disclosures would be made as appropriate, but no  provision would be made by the Group. Astellas Pharma US, Inc. (APUS), one of the Company’s indi- rect US subsidiaries, was named as a defendant in 2011 in  several separate lawsuits brought by plaintiffs in various federal  courts on behalf of themselves and proposed classes of all  direct and indirect purchasers of Prograf. These lawsuits  involve allegations that under the federal antitrust laws and  various state laws, APUS misused the Citizen Petition process  for the sole purpose of delaying the approval of generic tacroli- mus by the U.S Food and Drug Administration, thereby injuring  the plaintiffs. In June 2011, the US Judicial Panel on Multi- District Litigation ordered that the cases be consolidated  before the US District Court for the District of Massachusetts.  The case is being vigorously defended. The outcome of this  matter or its impact on our financial condition cannot be  determined at this time. Prograf Litigation (2) Compensation of key management personnel (Millions of yen) 2013 2014 Rewards and salaries ¥1,259 ¥1,276 Share-based payment 230 210 Other 226 188 Total compensation ¥1,715 ¥1,674